PMA device
Sphere-9 Catheter and Affera Ablation System
Medtronic, Inc. · Percutaneous Cardiac Ablation Catheter For Treatment Of Atrial Fibrillation With Irreversible Electroporation (QZI, Class III) · First FDA decision Oct 24, 2024, newest May 15, 2026Atrial fibrillation
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
9
Naming "Sphere-9"
MAUDE reports
339
Brand "Sphere-9", since 2015
PubMed studies
50
Mentioning "Sphere-9"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Sphere-9 Catheter and Affera Ablation System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- Sphere-9 Catheter and Affera Ablation SystemPMA supplement
P240013-S025 · Decided May 15, 2026 · 43 days after receipt · Normal 180 Day Track No User Fee
Device type: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation (QZI) · Cardiology
- Sphere-9 Catheter and Affera Ablation SystemPMA supplement
P240013-S007 · Decided May 30, 2025 · 29 days after receipt · Normal 180 Day Track No User Fee
Device type: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation (QZI) · Cardiology
- Sphere-9 Catheter and Affera Ablation SystemPMA supplement
P240013-S003 · Decided Feb 3, 2025 · 73 days after receipt · Normal 180 Day Track No User Fee
Device type: Percutaneous Cardiac Ablation Catheter for Treatment of Atrial Fibrillation with Irreversible Electroporation (QZI) · Cardiology
1 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Percutaneous Left Atrial Appendage Closure (LAAC)National determinationOn the books20.34Updated Nov 4, 2026
- Percutaneous Left Atrial Appendage (LAA) Closure TherapyNational analysisReview closedCAG-00445NUpdated Sep 21, 2026
- Cardiac Catheterization Performed In Other Than A Hospital SettingNational analysisReview closedCAG-00166NUpdated Sep 16, 2026
- Cardiac Catheterization Performed in Other than a Hospital Setting - RETIREDNational determinationOn the books20.25Updated Dec 3, 2024
- Cardiac Catheterization and Coronary AngiographyLocal determinationIn effectL33959CGS Administrators, LLCUpdated Oct 30, 2026
- Cardiac Catheterization and Coronary AngiographyLocal determinationIn effectL33557Wellpoint FederalUpdated Jul 14, 2026
- Percutaneous minimally invasive fusion/stabilization of the sacroiliac joint for the treatment of back painLocal determinationIn effectL36000WPS Insurance CorporationUpdated May 21, 2026
- Irreversible Electroporation for CancerLocal determinationIn effectL40205Palmetto GBAUpdated May 14, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Sphere-9", any status and sponsor, newest update first.
Medtronic Cardiac Ablation SolutionsPublic (MDT)
NCT07585968 · 260 participants (planned) · Start Aug 17, 2026 · Primary completion Mar 2028
Device: Sphere-9 Catheter with the Affera Mapping and Ablation System · For: Ventricular Tachycardia
Sites: Littleton, Colorado; Indianapolis, Indiana; Manhasset, New York · 7 sites in all
Medtronic Cardiac Ablation SolutionsPublic (MDT)
NCT07298473 · 400 participants (planned) · Start Apr 8, 2026 · Primary completion Mar 29, 2028
Device: Sphere-9 Catheter Ablation · For: Atrial Fibrillation (AF); Persistent Atrial Fibrillation; Paroxysmal Atrial Fibrillation (PAF)
Sites: Birmingham, Alabama; La Jolla, California; Los Angeles, California · 30 sites in all
Medtronic Cardiac Ablation SolutionsPublic (MDT)
NCT06703489 · 60 participants (planned) · Start Mar 18, 2025 · Primary completion Nov 2026
Device: Sphere-9 Catheter with the Affera Mapping and Ablation System · For: Ventricular Tachycardia (VT)
Sites: Boston, Massachusetts; New York, New York; Cleveland, Ohio · 6 sites in all
6 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Sphere-9", and for the whole product code for context.
This brand
339 reports: 159 malfunction, 160 injury, 8 death
Whole product code QZI
10,522 reports: 5,457 malfunction, 4,777 injury, 245 death
Newest reports for this brand
- Sphere-9Injury
9612164-2026-05338 · Received Oct 29, 2026 · Event dated Jan 28, 2026
Device type: Percutaneous Cardiac Ablation Catheter For Treatment Of Atrial Fibrillation With Irreversible Electroporation (QZI)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Atrial Fibrillation
- Sphere-9Injury
3012520654-2026-00598 · Received Oct 29, 2026 · Event dated Oct 20, 2026
Device type: Percutaneous Cardiac Ablation Catheter For Treatment Of Atrial Fibrillation With Irreversible Electroporation (QZI)
Device problem as coded: Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Paresis
- Sphere-9Malfunction
3012520654-2026-00599 · Received Oct 29, 2026 · Event dated Oct 5, 2026
Device type: Percutaneous Cardiac Ablation Catheter For Treatment Of Atrial Fibrillation With Irreversible Electroporation (QZI)
Device problem as coded: Device Contamination with Chemical or Other Material
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
2 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
- Medtronic Sphere-9 Catheter, Model Number AFR-00001; catheter, percutaneous, cardiac ablation, for treatment of atrial flutter.Open, Classified
Z-1948-2026 · Started Mar 11, 2026 · Posted by FDA Apr 24, 2026
Reason given: Ventricular fibrillation (VF) occurred during radiofrequency (RF) therapy with the Medtronic Sphere-9 catheter in patients who have a Biotronik Implantable Cardioverter Defibrillator (ICD) or Biotronik Cardiac Resynchronization Therapy-Defibrillator (CRT-D) implanted. The observation is caused by an interaction...
Cause as FDA categorized it: Device Design · Device type: Catheter, Percutaneous, Cardiac Ablation, For Treatment Of Atrial Flutter (OAD)
Published research
The most relevant PubMed records for "Sphere-9"[tiab]. The summary above synthesizes these.
- Real-World Adverse Events Associated With the Sphere-9 Dual-Energy Arrhythmia Ablation Catheter.
Morgan AA, Adhikari S, Alper A, et al. · J Cardiovasc Electrophysiol · 2026
- Pulsed Field Ablation-Related Hemolysis: Comparison Between Technologies.
Gianni C, Al-Ahmad A, Elchouemi M, et al. · Circ Arrhythm Electrophysiol · 2025Comparative Study
- A Focal Ablation Catheter Toggling Between Radiofrequency and Pulsed Field Energy to Treat Atrial Fibrillation.
Reddy VY, Peichl P, Anter E, et al. · JACC Clin Electrophysiol · 2023Research Support, Non-U.S. Gov't
- Mapping and ablation of ventricular tachycardia using dual-energy lattice-tip focal catheter: early feasibility and safety study.
Peichl P, Wichterle D, Schlosser F, et al. · Europace · 2024
- Safety and Feasibility of Pulsed-Field Ablation in Patients With Mechanical Prosthetic Valves.
Scacciavillani R, Della Rocca DG, Nair D, et al. · JACC Clin Electrophysiol · 2025Multicenter Study, Research Support, Non-U.S. Gov't
- Effect of Pulsed-Field and Radiofrequency Ablation on Heterogeneous Ventricular Scar in a Swine Model of Healed Myocardial Infarction.
Younis A, Zilberman I, Krywanczyk A, et al. · Circ Arrhythm Electrophysiol · 2022
- Short-Term Procedural Outcomes of Posterior Wall Isolation Using the Affera Pulse Field Ablation System.
Thakur U, Junker J, Koh Y, et al. · J Cardiovasc Electrophysiol · 2026
- Catheters and Tools with Pulsed Field Ablation-Pulmonary Vein Isolation with Focal Lattice-Tip Affera Sphere 9.
Cespón-Fernández M, Sarkozy A · Card Electrophysiol Clin · 2025Review, Research Support, Non-U.S. Gov't
- Use of a large-area focal lattice-tip catheter for cavotricuspid isthmus ablation.
Thalmann G, Kueffer T, Storz T, et al. · Heart Rhythm · 2026
- Safety, Efficacy, and Mid-Term Outcomes of Pulsed Field Ablation for Cavotricuspid Isthmus-Dependent Flutter: Real-World Data From a Major Health System Registry.
Rodriguez-Riascos JF, Vemulapalli HS, Prajapati P, et al. · Circ Arrhythm Electrophysiol · 2025Multicenter Study
- Thermal profiles of pulsed field ablation catheters.
Valappil SP, Kakarla SK, Puvrez A, et al. · Heart Rhythm · 2026
- Hemolysis Related to PFA: Comparative Study of Next-Generation Nanosecond With Conventional PFA Systems.
Marino M, Chiarazzo E, La Fazia VM, et al. · JACC Clin Electrophysiol · 2026
Other devices of this type
Also filed under product code QZI.
- FARAPULSE Pulsed Field Ablation System (FARAWAVE Pulsed Field Ablation CatheterFarapulse, Inc. · PMA 2026
- Volt PFA SystemAbbott Medical · PMA 2026
- VARIPULSE Catheter, TRUPULSE Generator with Connection Interface Unit (CIU)Biosense Webster, Inc. · PMA 2026
- PulseSelect Pulsed Field Ablation (PFA) systemMedtronic, Inc. · PMA 2026
- Globe® Catheter and Globe® Pulsed Field SystemKardium, Inc. · PMA 2026
- PulseSelect Pulse Field Ablation (PFA) CatheterMedtronic, Inc. · PMA 2026
- FARASTAR Pulsed Field Ablation (PFA) GeneratorFarapulse, Inc. · PMA 2025
- Globe® Pulsed Field SystemKardium, Inc. · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.